The company uses its ImmTOR immune tolerance platform to selectively mitigate unwanted immune responses, which has the potential to amplify the efficacy of biologic therapies and restore the body's natural self-tolerance in autoimmune diseases. Selecta's pipeline includes proprietary and partnered programs focused on enzyme therapies, gene therapies, and autoimmune diseases, such as Chronic Severe Gout and Ornithine Transcarbamylase Deficiency (OTC).